Biospectra
Biospectra, a leading provider of high-quality biopharmaceutical raw materials, is headquartered in the United States with significant operations in Europe and Asia. Founded in 2001, the company has established itself within the biotechnology and pharmaceutical industries, focusing on the production of cell culture media, buffers, and other critical components for bioprocessing. Biospectra's unique offerings include custom manufacturing solutions and a commitment to quality that meets stringent regulatory standards. The company has achieved notable milestones, including ISO certification and a robust portfolio of products that cater to the evolving needs of its clients. With a strong market position, Biospectra continues to be a trusted partner for organisations seeking reliable and innovative solutions in the biopharmaceutical sector.
DitchCarbon Score
How does Biospectra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biospectra's score of 18 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Biospectra's reported carbon emissions
Biospectra has not disclosed specific carbon emissions data for the most recent year. However, the company has made significant climate commitments aimed at reducing its greenhouse gas (GHG) emissions. Biospectra is committed to achieving a 42% reduction in Scope 1 and Scope 2 emissions by 2030, using 2022 as the baseline year. This target has been validated by the Science Based Targets initiative (SBTi) and aligns with the necessary reductions to limit global warming to 1.5°C. In addition to its Scope 1 and Scope 2 targets, Biospectra is also focused on measuring and reducing its Scope 3 emissions, which encompass indirect emissions from its value chain. These commitments reflect the company's proactive approach to addressing climate change and its dedication to sustainability within the pharmaceuticals, biotechnology, and life sciences sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biospectra is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
